top of page


1.: Stein M, Nemet A, Kumar S, Lumry W, Gajek H, Macchia R, Zamfirova V, Bergman G, McNeil D, Hooper J, Moy J, Pesek R, Upton J, Shapiro R, Sussman G, Roifman CR
Efficacy, Safety and Tolerability of Kedrion 10% IVIG in Primary Immunodeficiency
LymphoSign J 2016; 3: 99-109

2.: Planitzer CB, Säemann MD, Gajek H, Farcet MR, Kreil TR
Cytomegalovirus neutralization by hyperimmune and standard intravenous immunoglobulin preparations
Transplantation 2011; 92(3): 267-70

3.: Oldenburg J, Goudemand J, Valentino L, Richards M, Luu H, Kriukov A, Gajek H, Spotts G, Ewenstein B

Postauthorization safety surveillance of ADVATE (antihaemophilic factor (recombinant), plasma/albumin-free method) demonstrates efficacy, safety and low-risk for immunogenicity in routine clinical practice 

Haemophilia 2010, 1-12, DOI: 10.1111/j.1365-2516.2010.02332.x 

4.: Safety profile of SUBCUVIA in Children <12 Years from Post-Authorisation Safety Surveillance

Herlin T, Gajek H, Mattauch M, Gustafson R

Poster presented at XIII Meeting of the European Society for Immundeficiency, s’Hertogenbosch/The Netherlands 16-18. October 2008

5.: Antihemophilic factor (recombinant), plasma/albumin-free method (rAHF_PFM) experience assessed through ongoing post-authorization safety surveillance (PASS)

H Gajek, H Luu, B Ewenstein, A Kriukov, K Barker, R Berg, D Stephens, G Spotts

Poster presentetd at XXI Congress of the International Society of Thrombosis and Haemostasis, Geneva, 6.-12. July 2007

6.: Physicians’ perspective on current clinical and future uses: Plasma-derived medicinal products: Rare plasma protein disorders

Gajek H. in: Valverde JL (Ed.), Pharmaceutical Policy and Law: Blood, Plasma and Plasma Proteins, a Unique Contribution to Modern Healthcare; Vol 7, 

IOS Press Amsterdam 2005/2006

7.: Recommendations for postmarketing surveillance studies in haemophilia and other bleeding disorders

Lassila R, Rothschild C, de Moerloose P, Richards M, Perez R, and Gajek H, on behalf of the European Haemophilia Therapy Standardisation Board (EHTSB)

Haemophilia 2005; 11: 353-359

8.: Early and late histamine release induced by albumin, hetastarch and polygeline: some unexpected findings.

Celik I, Duda D, Stinner B, Kimura K, Gajek H, Lorenz W.

Inflamm Res. 2003 Oct; 52(10):408-16

9.: From clinical evidence to everyday practice: implementing findings from a cost-effectiveness analysis for endoscopic injection therapy for upper-gastrointestinal bleeding.

Sitter H, Lorenz W, Nicolay U, Krack W, Hellenbrandt A, Zielke A, Gajek H,Ledertheil G; Study Group Fibrin Glue Injection.

Eur J Gastroenterol Hepatol.  2003 Mar;15(3):295-304.  

10.: Plasma histamine levels during plasmapheresis: difficult interpretation of adverse reactions to plasma substitutes.

Celik I, Krack W, Zeiler T, Kretschmer V, Solinas S, Gajek H, Lorenz W.

Inflamm Res.  2001 Apr;50 Suppl 2:S65-7.  

11.: Antithrombin III modulator of coagulation and inflammatory reaction.

Gajek H.

Acta Anaesthesiol Scand Suppl.  1997;111:221-2.  

12.: Cardiac arrest following Haemaccel--comment.

Gajek H.

Anaesth Intensive Care. 1994 Feb;22(1):90-2.

13.: [Axillary brachial plexus block with lidocaine HCl and carbonated lidocaine]

[Article in German]

Hartung HJ, Gajek H, Ungemach J, Osswald PM

Reg Anaesth.  1986 Apr;9(2):35-7. 

bottom of page